 Home > Active Ingredient News > Blood System > BCL-2 inhibitor Venetoclax is fully approved by the FDA for the treatment of acute myeloid leukemia (AML)

BCL-2 inhibitor Venetoclax is fully approved by the FDA for the treatment of acute myeloid leukemia (AML)

 Last Update: 2020-10-27
 Source: Internet
 Author: User

Tags

astrocytoma survival rate

a cabinets

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, the FDA has approved a combination of Venetoclax with azatsin, tesitalbin, or low-dose LDAC for the treatment of patients over 75 years of age with acute myeloid leukemia (AML), who are not suitable for intensive induction chemotherapy.
AbbVie said data from phase III VIALE-A and VIALE-C trials supported the full approval.
VIALE-A study assessed the total survival rate (OS) of 431 AML patients who were not suitable for standard-induced chemotherapy, who were randomly assigned to venclexta combined azatide or placebo combined azaside therapy.
results showed that the risk of death was reduced by 34% compared to the combined placebo of Azaxta, with a medium OS of 14.7 months in patients treated with Venclexta and 9.6 months in the placebo group.
addition, the rate of complete remission (CR) was 37 per cent for patients treated with Venclexta, 18 per cent for CR and 13.4 months for CR in the placebo group.
viaLE-A results were presented at this year's Virtual Conference of the European Society of Hematology (EHA) and were recently presented at NEJM.
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$30.00/G FOB

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.